Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
AKESO Leaps 12%+; 2 Blockbuster Bi-specific Antibodies Expected to Cover 2K Hospitals This Yr
Recommend 3 Positive 3 Negative 1 |
||||
|
||||
|
Xia Yu, chairwoman of AKESO (09926.HK), noted that this year marks the company's first year entering the healthcare insurance sector, with two of its core bi-specific antibodies, cadonilimab and ivonescimab, remaining in the rapid growth phase. AKESO opened 0.52% higher today (1st) and once hit a peak of $88.1. It last traded at $85.7, up 12.47%, on a volume of 16.9488 million shares, involving $1.403 billion. Xia also mentioned that the two blockbuster products, cadonilimab and ivonescimab, will bring significant sales and profit returns to the company over the next decade or even longer. They are expected to cover 2,000 hospitals this year. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
